Clinical and pharmacokinetic evaluation of satraplatin

Bibliography

• Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007;7(8):573-84
   PubMed Web of Science ®Google Scholar
• Kelland L. Broadening the clinical use of platinum drug-based chemotherapy with new analogues. Satraplatin and picoplatin. Expert Opin Investig Drugs 2007;16(7):1009-21
   PubMed Web of Science ®Google Scholar
• Taylor AE, Wiltshaw E, Gore ME, Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer. J Clin Oncol 1994;12(10):2066-70
   PubMed Web of Science ®Google Scholar
• Skarlos DV, Samantas E, Kosmidis P, Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. Ann Oncol 1994;5(7):601-7
   PubMed Web of Science ®Google Scholar
• Horwich A, Sleijfer DT, Fossa SD, Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 1997;15(5):1844-52
   PubMed Web of Science ®Google Scholar
• Galsky MD, Chen GJ, Oh WK, Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann Oncol 2011 May 4; [Epub ahead of print]
   Web of Science ®Google Scholar
• Ardizzoni A, Boni L, Tiseo M, Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007;99(11):847-57
   PubMed Web of Science ®Google Scholar
• de Gramont A, Figer A, Seymour M, Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18(16):2938-47
   PubMed Web of Science ®Google Scholar
• McKeage MJ, Morgan SE, Boxall FE, Lack of nephrotoxicity of oral ammine/amine platinum (IV) dicarboxylate complexes in rodents. Br J Cancer 1993;67(5):996-1000
   PubMed Web of Science ®Google Scholar
• McKeage MJ, Boxall FE, Jones M, Harrap KR. Lack of neurotoxicity of oral bisacetatoamminedichlorocyclohexylamine-platinum(IV) in comparison to cisplatin and tetraplatin in the rat. Cancer Res 1994;54(3):629-31
   PubMed Web of Science ®Google Scholar
• McKeage MJ, Kelland LR, Boxall FE, Schedule dependency of orally administered bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in vivo. Cancer Res 1994;54(15):4118-22
   PubMed Web of Science ®Google Scholar
• Kelland LR, Abel G, McKeage MJ, Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug. Cancer Res 1993;53(11):2581-6
   PubMed Web of Science ®Google Scholar
• Mellish KJ, Kelland LR, Harrap KR. In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin. Br J Cancer 1993;68(2):240-50
   PubMed Web of Science ®Google Scholar
• Twentyman PR, Wright KA, Mistry P, Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin. Cancer Res 1992;52(20):5674-80
   PubMed Web of Science ®Google Scholar
• Wosikowski K, Lamphere L, Unteregger G, Preclinical antitumor activity of the oral platinum analog satraplatin. Cancer Chemother Pharmacol 2007;60(4):589-600
   PubMed Web of Science ®Google Scholar
• Mellish KJ, Barnard CF, Murrer BA, Kelland LR. DNA-binding properties of novel cis- and trans platinum-based anticancer agents in 2 human ovarian carcinoma cell lines. Int J Cancer 1995;62(6):717-23
   PubMed Web of Science ®Google Scholar
• Perry J, Powles T, Shamash J, The relative activity of cisplatin, oxaliplatin and satraplatin in testicular germ cell tumour sensitive and resistant cell lines. Cancer Chemother Pharmacol 2009;64(5):925-33
   PubMed Web of Science ®Google Scholar
• Mellish KJ, Kelland LR. Mechanisms of acquired resistance to the orally active platinum-based anticancer drug bis-acetato-ammine-dichloro-cyclohexylamine platinum (i.v.) (JM216) in two human ovarian carcinoma cell lines. Cancer Res 1994;54(23):6194-200
   PubMed Web of Science ®Google Scholar
• Rose WC. Combination chemotherapy involving orally administered etoposide and JM-216 in murine tumor models. Cancer Chemother Pharmacol 1997;40(1):51-6
   PubMed Web of Science ®Google Scholar
• Rose WC, Crosswell AR, Schurig JE, Casazza AM. Preclinical antitumor activity of orally administered platinum (IV) complexes. Cancer Chemother Pharmacol 1993;32(3):197-203
   PubMed Web of Science ®Google Scholar
• Kelland LR. An update on satraplatin: the first orally available platinum anticancer drug. Expert Opin Investig Drugs 2000;9(6):1373-82
   PubMed Web of Science ®Google Scholar
• Choy H, Park C, Yao M. Current status and future prospects for satraplatin, an oral platinum analogue. Clin Cancer Res 2008;14(6):1633-8
   PubMed Web of Science ®Google Scholar
• Sova P, Mistr A, Kroutil A, A comparative study of pharmacokinetics, urinary excretion and tissue distribution of platinum in rats following a single-dose oral administration of two platinum(IV) complexes LA-12 (OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum(IV) and satraplatin (OC-6-43)-bis(acetato)amminedichloro(cyclohexylamine)platinum(IV). Cancer Chemother Pharmacol 2011;67(6):1247-56
   PubMed Web of Science ®Google Scholar
• Poon GK, Raynaud FI, Mistry P, Metabolic studies of an orally active platinum anticancer drug by liquid chromatography-electrospray ionization mass spectrometry. J Chromatogr A 1995;712(1):61-6
   PubMed Web of Science ®Google Scholar
• Sharp SY, Rogers PM, Kelland LR. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance. Clin Cancer Res 1995;1(9):981-9
   PubMed Web of Science ®Google Scholar
• Marcus L, Murphy R, Fox E, The plasma and cerebrospinal fluid pharmacokinetics of the platinum analog satraplatin after intravenous administration in non-human primates. Cancer Chemother Pharmacol 2011 Jun 26; [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• O'Neill CF, Koberle B, Masters JR, Kelland LR. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin. Br J Cancer 1999;81(8):1294-303
   PubMed Web of Science ®Google Scholar
• Kostrhunova H, Kasparkova J, Gibson D, Brabec V. Studies on cellular accumulation of satraplatin and its major metabolite JM118 and their interactions with glutathione. Mol Pharm 2010;7(6):2093-102
   PubMedGoogle Scholar
• Raynaud FI, Odell DE, Kelland LR. Intracellular metabolism of the orally active platinum drug JM216: influence of glutathione levels. Br J Cancer 1996;74(3):380-6
   PubMed Web of Science ®Google Scholar
• Kostrhunova H, Vrana O, Suchankova T, Different features of the DNA binding mode of antitumor cis-amminedichlorido(cyclohexylamine)platinum(II) (JM118) and cisplatin in vitro. Chem Res Toxicol 2010;23(11):1833-42
   PubMed Web of Science ®Google Scholar
• Fink D, Nebel S, Aebi S, The role of DNA mismatch repair in platinum drug resistance. Cancer Res 1996;56(21):4881-6
   PubMed Web of Science ®Google Scholar
• McKeage MJ. Satraplatin in hormone-refractory prostate cancer and other tumour types: pharmacological properties and clinical evaluation. Drugs 2007;67(6):859-69
   PubMed Web of Science ®Google Scholar
• Samimi G, Kishimoto S, Manorek G, Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin. Cancer Chemother Pharmacol 2007;59(3):301-12
   PubMed Web of Science ®Google Scholar
• Ando Y, Shimizu T, Nakamura K, Potent and non-specific inhibition of cytochrome P450 by JM216, a new oral platinum agent. Br J Cancer 1998;78(9):1170-4
   PubMed Web of Science ®Google Scholar
• McKeage MJ, Mistry P, Ward J, A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration. Cancer Chemother Pharmacol 1995;36(6):451-8
   PubMed Web of Science ®Google Scholar
• McKeage MJ, Raynaud F, Ward J, Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer. J Clin Oncol 1997;15(7):2691-700
   PubMed Web of Science ®Google Scholar
• Beale P, Raynaud F, Hanwell J, Phase I study of oral JM216 given twice daily. Cancer Chemother Pharmacol 1998;42(2):142-8
   PubMed Web of Science ®Google Scholar
• Sessa C, Minoia C, Ronchi A, Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days. Ann Oncol 1998;9(12):1315-22
   PubMed Web of Science ®Google Scholar
• Vouillamoz-Lorenz S, Buclin T, Lejeune F, Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days. Anticancer Res 2003;23(3C):2757-65
   PubMed Web of Science ®Google Scholar
• Ricart AD, Sarantopoulos J, Calvo E, Satraplatin, an oral platinum, administered on a five-day every-five-week schedule: a pharmacokinetic and food effect study. Clin Cancer Res 2009;15(11):3866-71
   PubMed Web of Science ®Google Scholar
• Galsky MD, Camacho LH, Chiorean EG, Phase I study of the effects of renal impairment on the pharmacokinetics and safety of satraplatin in patients with refractory solid tumors. Ann Oncol 2011 Aug 9; [Epub ahead of print]
   Web of Science ®Google Scholar
• Jones S, Hainsworth J, Burris HA III, Phase I study of JM-216 (an oral platinum analogue) in combination with paclitaxel in patients with advanced malignancies. Invest New Drugs 2002;20(1):55-61
   PubMed Web of Science ®Google Scholar
• DeMario MD, Ratain MJ, Vogelzang NJ, A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days. Cancer Chemother Pharmacol 1999;43(5):385-8
   PubMed Web of Science ®Google Scholar
• Choy H, Hughes RS, Dimaio M, Phase I study of oral platinum with concurrent radiation therapy in non small cell lung cancer. J Clin Oncol 2008;26(20 Suppl):abstract 7560
   PubMedGoogle Scholar
• Cmelak AJ, Choy H, Murphy BA, Phase I study of JM-216 with concurrent radiation in non-small cell lung cancer and squamous cell head and neck cancer. J Clin Oncol 1999;abstract 1520,18:393a
   Google Scholar
• Gallerani E, Bauer J, Hess D, A phase I study of the oral platinum agent satraplatin in sequential combination with capecitabine in the treatment of patients with advanced solid malignancies. Acta Oncol 2011 Oct; 50(7):1105-10
   PubMed Web of Science ®Google Scholar
• Cetnar J, Wilding G, McNeel D, A phase 1/1b study of satraplatin (JM-216) in combination with docetaxel in patients with advanced solid tumors and metastatic castrate-resistant prostate cancer. Urologic oncology
   Google Scholar
• Deshpande HA, Gettinger S, Rowen E, A phase I study investigating the combination of orally bioavailable platinum and nanoparticle albumin-bound paclitaxel in advanced solid tumors. J Clin Oncol 2009;27(Suppl):abstract e13501
   Google Scholar
• Di Paola ED, Alonso S, D'Alessio A, Dose finding study of the combination of satraplatin and gemcitabine in patients with advanced solid tumors. J Clin Oncol 2009;27(Suppl):abstract e13534
   Google Scholar
• Fokkema E, Groen HJ, Bauer J, Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer. J Clin Oncol 1999;17(12):3822-7
   PubMed Web of Science ®Google Scholar
• Fokkema E, de Vries EG, Meijer S, Groen HJ. Lack of nephrotoxicity of new oral platinum drug JM216 in lung cancer patients. Cancer Chemother Pharmacol 2000;45(1):89-92
   PubMed Web of Science ®Google Scholar
• Judson I, Cerny T, Epelbaum R, Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: an EORTC early clinical studies group investigation. Ann Oncol 1997;8(6):604-6
   PubMed Web of Science ®Google Scholar
• Thompson DS, Spigel DR, Hainsworth JD, Phase II trial of satraplatin (S) and paclitaxel (P) in first-line advanced non-small cell lung cancer (NSCLC) treatment: final results. J Clin Oncol 2008;26(20 Suppl):abstract 19023
   PubMedGoogle Scholar
• Schiller JH, Harrington D, Belani CP, Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346(2):92-8
   PubMed Web of Science ®Google Scholar
• Smith JW II, McIntyre KJ, Acevedo PV, Results of a phase II open-label, nonrandomized trial of oral satraplatin in patients with metastatic breast cancer. Breast Cancer Res Treat 2009;118(2):361-7
   PubMed Web of Science ®Google Scholar
• Latif T, Wood L, Connell C, Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC). Invest New Drugs 2005;23(1):79-84
   PubMed Web of Science ®Google Scholar
• Vaishampayan UN, Heilbrun L, Dickow B, Phase II trial of bevacizumab (B) and oral satraplatin (S) and prednisone in docetaxel pretreated metastatic castrate resistant prostate cancer (CRPC). J Clin Oncol 2011;29(Suppl 7):abstract 152.
   Google Scholar
• Galsky MD, Seng S, Camacho LH, Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy. Clin Genitourin Cancer 2011;9(1):27-30
   PubMed Web of Science ®Google Scholar
• Trudeau M, Stuart G, Hirte H, A phase II trial of JM-216 in cervical cancer: an NCIC CTG study. Gynecol Oncol 2002;84(2):327-31
   PubMed Web of Science ®Google Scholar
• Canobbio L, Guarneri D, Miglietta L, Carboplatin in advanced hormone refractory prostatic cancer patients. Eur J Cancer 1993;29A(15):2094-6
   PubMed Web of Science ®Google Scholar
• Miglietta L, Cannobbio L, Boccardo F. Assessment of response to carboplatin in patients with hormone-refractory prostate cancer: a critical analysis of drug activity. Anticancer Res 1995;15(6B):2825-8
   PubMed Web of Science ®Google Scholar
• Trump DL, Marsh JC, Kvols LK, A phase II trial of carboplatin (NSC 241240) in advanced prostate cancer, refractory to hormonal therapy. An Eastern Cooperative Oncology Group pilot study. Invest New Drugs 1990;8(Suppl 1):S91-4
   PubMedGoogle Scholar
• Oh WK, Tay MH, Huang J. Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer? Cancer 2007;109(3):477-86
   PubMed Web of Science ®Google Scholar
• Ross RW, Beer TM, Jacobus S, A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer 2008;112(3):521-6
   PubMed Web of Science ®Google Scholar
• Oh WK, Halabi S, Kelly WK, A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813. Cancer 2003;98(12):2592-8
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Whelan P, Hetherington J, Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology 2005;68(1):2-9
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Petrylak DP, Sartor O, Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 2009;27(32):5431-8
   PubMed Web of Science ®Google Scholar
• Korn EL, Freidlin B, Abrams JS. Overall survival as the outcome for randomized clinical trials with effective subsequent therapies. J Clin Oncol 2011;29(17):2439-42
   PubMed Web of Science ®Google Scholar
• Wheate NJ, Walker S, Craig GE, Oun R. The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans 2010 Sep 21; 39(35):8113-27
   PubMed Web of Science ®Google Scholar
• Ciuleanu T, Samarzjia M, Demidchik Y, Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first-line platinum-based chemotherapy. J Clin Oncol 2010;28(Suppl 15s):abstract 7002
   Google Scholar
• Olaussen KA, Dunant A, Fouret P, DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006;355(10):983-91
   PubMed Web of Science ®Google Scholar
• Soria JC. ERCC1-tailored chemotherapy in lung cancer: the first prospective randomized trial. J Clin Oncol 2007;25(19):2648-9
   PubMed Web of Science ®Google Scholar
• Ruzzo A, Graziano F, Loupakis F, Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 2007;25(10):1247-54
   PubMed Web of Science ®Google Scholar
• Huang RS, Johnatty SE, Gamazon ER, Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin Cancer Res 2011;17(16):5490-500
   PubMed Web of Science ®Google Scholar